title: Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels.
abstract: Acute liver toxicity is a frequent adverse event that occurs during antiretroviral therapy and was observed in 6-30% of the patients on treatment, especially in presence of HCV coinfection (Cooper et al., 2002, Maida et al., 2006, Sulkowski et al., 2000). A correlation between HCV-associated liver-fibrosis severity and the risk of HAART associated hepatoxicity has been demonstrated (Aranzabal et al., 2005, Sulkowski et al., 2004). This high liver toxicity rate might be due to increased drug exposure in patients with liver disease (Veronese et al., 2000). It has been reported that patients with chronic hepatitis C show significantly reduced CPY3A4 and CYP2D6 activity in comparison with healthy volunteers (Becquemont et al., 2002). The aim of this study was to evaluate the liver function tests in HCV-co-infected patients treated with fos-amprenavir and ritonavir.
authors.affiliation: Infectious Disease Department, San Raffaele Scientific Institute and Università Vita-Salute San Raffaele Milan, Italy. vincenzo.spagnuolo@tiscali.it
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Spagnuolo
authors.forename: Gianluca
authors.initials: G
authors.lastname: Gentilini
authors.forename: Anna
authors.initials: A
authors.lastname: De Bona
authors.forename: Laura
authors.initials: L
authors.lastname: Galli
authors.forename: Caterina
authors.initials: C
authors.lastname: Uberti-Foppa
authors.forename: Armando
authors.initials: A
authors.lastname: Soldarini
authors.forename: Fernanda
authors.initials: F
authors.lastname: Dorigatti
authors.forename: Elena
authors.initials: E
authors.lastname: Seminari
mesh_terms: D000328:Adult; D000998:Antiviral Agents; D002219:Carbamates / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid; D005663:Furans; D006678:HIV; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification; D006515:Hepatitis B virus / Q000235:genetics / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000150:complications / Q000378:metabolism; D006801:Humans; D008103:Liver Cirrhosis / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology*; D008875:Middle Aged; D019438:Ritonavir / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D013449:Sulfonamides / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016896:Treatment Outcome